Insmed inc
INSM 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
INSM 近期報酬表現
-0.48%
Insmed inc
6.23%
同產業平均
1.02%
S&P500
與 INSM 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
PTCT | Ptc therapeutics inc | 2 分 | 3 分 | 3 分 | 3 分 | 1 分 | |
FOLD | Amicus therapeutics, inc | 3 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
NMRA | Neumora therapeutics inc | - | 2 分 | 1 分 | 2 分 | 1 分 | |
DNLI | Denali therapeutics inc | 4 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
VCYT | Veracyte inc | 3 分 | 1 分 | 2 分 | 2 分 | 1 分 |
- PTCT Ptc therapeutics inc價值 2 分趨勢 3 分波段 3 分籌碼 3 分股利 1 分查看更多
INSM 公司資訊
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).